Supplementary data.

Contains:

Figs S1 and S2 Tables S1-S4

Supplementary Figure legends

Figure S1. Chromatograms showing *POLE* and *POLD1* EDMs reported in this study. The upper reads in each panel are the reference sequence generated by the Mutation Surveyor program.

Figure S2. Sequence alignment of human POLE exonuclease domain (residues 268-471) and orthologues with exo motifs highlighted and invariant residues indicated by asterisks. Mutated residues detected in this study and the TCGA dataset are indicated.

Figure S1.











Figure S2

Human Mus musculus Danio rerio Xenopus Drosophila C.Elegans S. pombe S.Cerevisiae	195 195 193 193 193 182 222 206	LQRGGVITDEEE-TSKKIADQLDNIVDMREYDVPYHIRLSIDLKIHVAHWYNVRYR-GNAFPVEITRRDDLVERPDPVVL LQGGSVITDEDE-TSKKIADQLDNIVDMREYDVPYHIRLSIDLKIHVAHWYNVRR-GNAFPVEITRRDDLVERPDPVVL LVGGSVVTEDEGGSSKKMTEQLDNILDMREYDVPYHVRVSIDLKIHVAHWYNVRYR-GSAYPPEIVRRDDLVERPDPVVL LTCNNNGAEEG-PSKKISDQMENIVDMREYDVPYHVRVSIDLKIHVAHWYNIRYR-GSSSPEITRRDDLVERPPPVVL LAGSSAGSEDAT-LGRQQDYMCIVDIREHDVPYHVRVSIDLKIHVAHWYNIRYR-GSSSPEITRRDDLVERPPPVVL LSGKGGDSKDQQLNGDILNQIVDIREHDVPYHVRVSIDLKIFVGLWYDVKGI-GPNRVPTIKRKDLPLFHAKPKVL IYNVANGSEKVDAKHLIEDIREYDVPYHMRVSIDKIFVGGWYTVSYHGGHVQISLLASRIFAADPVVM LNGIIENAFE	272 272 271 270 270 256 287 273
		D275 P286 S297	
Human	273	A FO T F T T T T T T T T T T T T T T T T	352
Mus musculus	273	A DID IT MALE DAD DE TOUTANT SYMTDOGOGYL TANDE TUSED I DE TANDE TO SE DE CONSEDERATION DE LA CONSEDERATIONE DE LA	352
Danio rerio	272	A DID TOTAL DAL DE DID TOTALI SUM DOCOCET. TANDE TO SED TEDET FOR DE VECDET TENEDO E VECDE TENEDO E VECDET TENEDO E VECDE TENEDO E V	351
Yenopus	271	A DID IT MALE DADIED THAT DADA DO DI TANDA VOLDE DEDIE TA MELE DADA DA DADA DA DADA DA DADA DA DADA DA	350
Drogonhila	271	A DID TATA DAL DAL DE DIDITATIONAL DO CONTRADO CONTRADO DE DE DE LA DELLA DE	350
C.Elegans	257	AFD FTTTL DLK FORESDE IMMI SYMUDGRGFLIINREIVSAD INAFEYTEKAFYI GEFTUWNEKDEAALI RKFFDHFL	336
S. nombe	288	AFD IFTTKPDI KEPDSAUDOTMMI SYMTDGGGFI.ITNREI I SED IEDFEYTPKDE VOGFFT IFNENDEVALLORFFEH IR	367
S.Cerevisiae	274	AFD FETTIL DLK FODSSFDK IMMI SYMIDGOGFLITNREI I SON FDFH YTDREFEGPT I FNEPDRVGLI.HRFFKH IR	353
	- · ·	****** ****** * ****** ** ** ***** * * *	
		Exol	
		V <u>41</u> 1 L <u>42</u> 4 A <u>42</u> 8	
Human	353	ETKPTIMVTYNGDFFDWPFVEARAAVHGLSMQQEIGFOKDSQGEYKAPQCIHMDCLRWVKRDSYLPVGSHNLKAAAKAKL	432
Mus musculus	353	ETKPTIMVTYNGDFFDWPFVEARAAIHGLSMYQEIGFOKDSOGEYKAPOCIHMDCLRWVKRDSYLPVGSHNLKAAAKAKL	432
Danio rerio	352	ETKPNIFVTYNGDFFDWPFVEARAAQLGLSMHREIGFOKDNOGEYKASQAIHMDCLRWVKRDSYLPVGSHNLKAAAKAKL	431
Xenopus	351	ETKPNIIVTYNGDFFDWPFVETRATVHGMSMLQEIGFQKDNQGEYKSPPCIHMDCLRWVKRDSYLPVGSHNLKAAAKAKL	430
Drosophila	351	EVRPHIIVTYNGDFFDWPFVETRAAVYDLDMKQEIGFSKLRDGNYLSRPAIHMDCLCWVKRDSYLPVGSQGLKAVAKAKL	430
C.Elegans	337	QVRPNIVVTYNGDFFDWPFVEARAKIRGFNMEREIGFSKDSADEYKSRNCIHMDAFRWVKRDSYLPVGSQNLKAVTKAKL	416
S. pombe	368	DVRPTVISTFNGDFFDWPFIHNRSKIHGLDMFDEIGFAPDAEGEYKSSYCSHMDCFRWVKRDSYLPQGSQGLKAVTQSKL	447
S.Cerevisiae	354	SAK <mark>PSVIVTYNGDFFDWPFV</mark> DARAAFHGLNLTEETGFFRDAEDEYKSSYCSHMDAFRWVKRDSYLPO <mark>GSOGLKAV</mark> TV <mark>SKL</mark>	433
		* * ******* * * ** * *** **************	
		Exo I Exo IV	
		M444 R446 Q453 A456 A465	
Human	433	GYDPVELDPEDMCRMATEQPQTLATYSVSDAVATYYLYMKYVHPFIFALCTIIPMEPDEVLRKGSGTLCEALLMVQAFHA	512
Mus musculus	433	GYDPVELDPEDMCRMATEQPQTLATYSVSDAVATYYLYMKYVHPFIFALCTIIPMEPDEVLRKGSGTLCEALLMVQAFHA	512
Danio rerio	432	GYDPVELDPEEMCRMATEEPOTLATYSVSDAVATYYLYMKYVHPFIFALCTIIPMEPDEVLRKGSGTLCEALLMVQAYHV	511
Xenopus	431	GYDPVELDPEEMCRMATEEPQVLATYSVSDAVAT YYMYMKYVHPFIFALCTIIPMEPDEVLRKGSGTLCEALLMVQAYHA	510
Drosophila	431	RYDPVELDPEDMCRMAVEQPQVLANYSVSDAVAT YYLYMKYVHPFIFALNTIIPMEPDEILRKGSGTLCETLLMVEAYHA	510
C.Elegans	417	RYDPVEVEPELMCKMAREQPQQLANYSVSDAVSTYYLYMKYVHQFIFALCTIIPLGADDVLRKGSGTLCEALLMVEAFHN	496
S. pombe	448	GYNPIELDPELMTPYAFEKPQHLSEYSVSDAVAT YYLYMKYVHPFIFSLCTIIPLNPDETLRKGTGTLCEMLLMVQAYQH	527
S.Cerevisiae	434	GYNPIELDPELMTPYASEKPQVLAQYSVSDAVAT YFLYMKYVHPFIFSLCNIIPLNPDEVLRKGTGTLCETLLTVEACTK	513
		* * * ** * * * * * * *** * ******* ** *	

Tumour ID	MSI	EDM status	Somatic mutation	Protein alteration
EC8	MSS	Non-mutant	PTEN c.518G>A	PTEN p.Arg173His
EC25	MSS	Non-mutant	<i>PIK3CA</i> c.3127A>G	PK3CA p.Met1043Val
			PIK3CA c.263G>A	PK3CA p.Arg88Gln
EC34	MSS	Non-mutant	<i>FBXW7</i> c.1385C>T¶	FBXW7 p.Ser462Phe¶
EC145	MSS	Non-mutant	<i>PIK3CA</i> c.278G>A	PK3CA p.Arg93Gln
			<i>PTEN</i> c.389G>A	PTEN p.Arg130Gln
EC71	MSS	POLE Pro286Arg	<i>FBXW7</i> c.751G>T	FBXW7 p.Glu251*
			<i>PTEN</i> c.766G>T	PTEN p.E256*
EC74	MSS	POLE Pro286Arg	<i>PIK3CA</i> c.3141T>G	PK3CA p.His1047Gln
			<i>PIK3CA</i> c.1070G>A	PK3CA p.Arg357Gln
EC167	MSS	POLE Pro286Arg	<i>FBXW7</i> c.1514G>T¶	FBXW7 p.Arg505Leu¶
EC173	MSS	POLE Ser297Phe	PIK3CA c.263G>A	PK3CA p.Arg88Gln
			<i>PIK3CA</i> c.3062A>G	PK3CA p.Tyr1021Cys
			<i>PTEN</i> c.388C>G	PTEN p.Arg130Gly

Table 51. Withations in LC unvergenes in non-LDW and TOLE-LDW cancers	Table S1.	Mutations in	EC drive	r genes in	non-EDM	and POL	<i>E</i> -EDM	cancers
---	-----------	--------------	----------	------------	---------	---------	---------------	---------

¶ Indicates variant validated by Sanger sequencing

Table S2. Site and predicted consequence of *POLE* and *POLD1* exonuclease domain mutations not detected in our panel but present in the TCGA EC set

Gene	Nucleotide	Amino acid	Number of	Site	SIFT score	PolyPhen-2	PhyloCons	MutationTaster score
	change	change	tumours			score	Score	
POLE	c.1270C>G	p.Leu424Val	2	Exo IV motif	0.01	0.993	1.00	0.87
	c.1282G>A	p.Ala428Thr	1	Exo IV motif	0.79	0.041	1.282	1.58
						(Benign)		
	c.1331T>A	p.Met444Lys	1	Between Exo III and V motifs	0.00	1.000	1.00	2.59
	c.1358A>G	p.Gln453Arg	1	Exo III motif	0.06	0.025 (benign)	1.00	1.17
	c.1394C>T	p.Ala465Val	1	Exo III motif	0.00	1.000	1.00	1.75
POLD1	c.1174G>A	p.Val392Met	1	Flanking Exo I motif	0.000	0.946	0.999	Polymorphism 0.57

Table S3. Frequency and type of base substitutions according to tumour POLE/POLD mutation status in TCGA dataset

	Proportion of total base substitutions, % (95 CI)						
Category	C>T	A>G	C>G	G>T	A>C	A>T	
	G>A	1>C	G>C	C>A	1>G	I>A	
No POLE/POLD1	59.1	11.8	8.7	13.5	3.5	3.4	173.9
mutation	(57.6-59.1)	(10.9-11.8)	(7.6-8.7)	(12.9-13.5)	(3.1-3.5)	(3-3.4)	(140-208)
POLE EDM							
p.Pro286Arg	42.9	7.6	0.3	37.4	11.1	0.8	7355.1
	(38.7-47)	(6.6-8.6)	(0.2-0.3)	(34.2-40.5)	(9.3-12.9)	(0.6-0.9)	(4887-9824)
p.Ser297Phe	56.4	6.4	0.1	32.4	3.5	1.2	12699
p.Val411Leu	55.1	10.8	0.5	23.3	9.5	0.7	7743
	(49.3-61)	(9.3-12.3)	(0.4-0.7)	(21-25.6)	(6.1-12.9)	(0.6-0.8)	(2474-13012)
p.Leu424Val	58.1	9.9	0.8	26.5	3.2	1.4	4749
p.Ala428Thr	59.3	3.7	11.1	11.1	11.1	3.7	27
p.Met444Lys	38.6	4.8	0.3	44.9	10.1	1.2	1523
p.Gln453Arg	65.1	20.0	0.9	10.0	1.5	2.5	976
p.Ala456Pro	60.1	8.3	0.3	25.1	5.0	1.3	8385
p.Ala465Val	85.0	5.3	0.4	8.3	0.5	0.6	5592
POLE non-ED	58.49	22.47	2.4	9.8	3.0	3.9	636
mutated	(40.1-76.9)	(4.8-40.2)	(0.6-4.2)	(5.8-13.8)	(1.4-4.5)	(2.0-5.9)	(205.0-1067.0)
POLD1 EDM							
p.Val392Met	81.3	9.8	1.3	5.7	0.9	1.1	1637
POLD1 non-ED	63.7	15.1 (8.6-	3.8	11.9 (8.7-	2.1	3.5	606
mutated	(59.0-68.4)	21.6)	(0.3-7.2)	15.2)	(0.7-3.4)	(2.3-4.7)	(72.5-1139.5)

Tumour ID	Gene	Protein alteration	Hypermutated	MLH1 methylation	Somatic mutation	Protein alteration
A05Z	POLE	p.Pro286Arg	+	-	PTEN c.389G>A, PTEN c.601G>T	PTEN p.Arg130Gln PTEN p.Glu201*
A0J0	POLE	p.Pro286Arg	+	-	CTNNB1 c.110C>G PTEN c.389G>A	CTNB1 p.Ser37Cys PTEN p.Arg130Gln
A0JY	POLE	p.Pro286Arg	+	-	CTNNB1 c.94G>T PTEN c 19G>T c 140delG	CTNB1 p.Asp32Tyr PTEN p Glu7* p Arg47fs
A11N	POLE	p.Pro286Arg	+	-	<i>FBXW7</i> c.1394G>A <i>KRAS</i> c.182A>T	FBXW7 p.Arg465His KRAS p.Gh61Leu
A0UF	POLE	p.Pro286Arg	+	-	PTEN c.19G>1: PTEN c.389G>A TP53 c.637C>T:	PTEN p.Gu/* PTEN p.Arg130Gln TP53 p.Arg213*
A0UV	POLE	p.Pro286Arg	+	-	<i>PIK3CA</i> c.263G>A <i>PTEN</i> c.389G>A, c.720C>G <i>TP53</i> c.637C>T	PK3CA p.Arg88Gln PTEN p.Arg130Gln, p.Tyr240* TP53 p.Arg213*
A16X	POLE	p.Pro286Arg	+	-	PTEN c.389G>A, c. 601G>T	PTEN p.Arg130Gln, p.Glu201*
A17Q	POLE	p.Pro286Arg	+	-	<i>FBXW7</i> c.711G>A <i>PIK3CA</i> c.353G>A <i>PTEN</i> c.1008C>A	FBXW7 p.Trp237* PK3CA p.Gly118Asp PTEN p.Tvr336*
A059	POLE	p.Ser297Phe	+	-	TP53 c.718A>G	TP53 p.Ser240Gly
A0GP	POLE	p.Val411Leu	+	-	FBXW7 c.1393C>T KRAS c.35G>T PIK3CA c.263G>A, c.353G>A PTEN c G389A c 697C>T	FBXW7 p.Arg465Cys KRAS p.Gly12Val PK3CA p.Arg88Gln, p.Gly118Asp PTEN p.Arg130Gln, p.Arg233*
A056	POLE	p.Val411Leu	+	-	<i>FBXW7</i> c.1105G>T <i>KRAS</i> c.38G>T <i>PIK3CA</i> c.263G>A, c.3062A>G <i>PTEN</i> c.389G>A	FBXW7 p.Glu369* KRAS p.Gly13Val PK3CA p.Arg88Gln, p.Tyr1021Cys PTEN p.Arg130Gln
A0LM	POLE	p.Val411Leu	+	-	FBXW7 c.1513C>G	FBXW7 p.Arg505Glv
A11E	POLE	p.Val411Leu	+	-	<i>KRAS</i> c.35G>T <i>PTEN</i> c.895G>T <i>TP53</i> c.1024C>T	KRAS p.Gly12Val PTEN p.Glu299* TP53 p.Arg342*
A16Y	POLE	p.Val411Leu	+	-	<i>FBXW7</i> c.1972C>T <i>PTEN</i> c.259C>T, c.389G>A <i>TP53</i> c.638G>A	FBXW7 p.Arg658* PTEN p.Gln87*, p.Arg130Gln TP53 p.Arg213Gln
A051	POLE	p.Leu424Val	+	+	Nil found	Nil found
A0VX	POLE	p.Leu424Val	-	-	<i>CTNNB1</i> c.94G>T <i>PIK3CA</i> c.1637A>G, c.263G>A	CTNB1p.Asp32Tyr PK3CA:p.Gln546Arg, p.Arg88Gln
A1DQ	POLE	p.Ala428Lys	-	-	<i>PIK3CA</i> c.317G>T <i>TP53</i> c.524G>A	PK3CA p.Gly106Val TP53 p.Arg175His
A0TC	POLE	p.Met444Lys	+	-	<i>KRAS</i> c.35G>T <i>PIK3CA</i> c.323G>A <i>PTEN</i> c 388C>G c 437T>A	KRAS p.Gly12Val PK3CA p.Arg108His PTEN p Arg130Gly p Leu146*
A11H	POLE	p.Gln453Arg	+/-	-	<i>PTEN</i> c.526_528del, c.606_607del	PTEN p.176_176del, p.202_203del
A103	POLE	p.Ala456Pro	+	+	<i>FBXW7</i> c.1972C>T, c.2065C>T <i>PTEN</i> c.19G>T	FBXW7 p.Arg658*X, p.Arg689Trp PTEN p.Glu7*
A0J1	POLE	p.Ala465Val	+	+	PTEN c.389G>A	PTEN p.Arg130Gln
A0VP	POLDI	p.Val392Met	+	-	<i>FBXV7</i> c.40C>T <i>PIK3CA</i> c.G263G>A, c.1625A>C <i>PTEN</i> c.518G>A, c.697C>T	FBXW7 p.Arg14* PK3CA p.Arg88Gln, p.Glu542Ala PTEN p.Arg173His, p.Arg233*

Table S4. Pattern of mutation of EC driver alterations in EDM tumours in TCGA dataset